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a b s t r a c t 
There are striking similarities between the dual pandemics of multidrug-resistant tuberculosis (MDR TB) 
and multidrug-resistant Gram negative bacilli (MDR GNB) despite fundamental differences in the patho- 
genesis and epidemiology of these pathogens. In this perspective, we highlight several strategies that 
have been used by the global TB community to address the MDR TB problem, including approaches to: 
encourage appropriate use of anti-TB medications, enhance appropriate utilization of molecular diagnos- 
tic testing, facilitate development of new antimicrobial agents, and strengthen surveillance systems and 
infection control practices. Understanding the successes and challenges of these strategies for MDR TB 
control will be instructive for efforts to curb emergence and spread of MDR GNB. 
© 2016 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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(  MDR TB and MDR GNB: disease burden 
MDR TB was ﬁrst recognized as a problem in the late 1990s
and now affects roughly 50 0,0 0 0 people annually, accounting for
3% of new TB cases and 20% of previously treated TB cases world-
wide [1] . Although 50% of the global burden of MDR TB occurs in
India, China, and the Russian Federation [1] ( Fig. 1 ), MDR TB and
extensively drug-resistant TB (XDR TB) have emerged and spread
worldwide, with transmission often facilitated through interna-
tional travel. Foreign-born individuals account for 90% of US MDR
TB cases [2] and stories of XDR TB patients traveling by commer-
cial airlines make headlines [3] . As there are few new, effective
drugs to treat these resistant strains, MDR/XDR TB patients receive
second line agents that are more toxic and costly, and less effec-
tive than ﬁrst line therapies. Globally, among patients with MDR
TB who are initiated on therapy, only about half are successfully
treated. In 2014 there were an estimated 190,0 0 0 deaths due to
MDR TB [1] 
While attention has been focused on MDR TB for decades, the
global emergence of other drug resistant bacteria has only recently
been recognized as a public health emergency [4] . The press in-
creasingly report stories about extensively drug-resistant bacteria
that are resistant to most existing antibiotics and are thought to∗ Corresponding author. Tel.: + 1 507 255 8464; fax: + 1 507 255 7767. 
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isors on Science and Technology published a report calling an-
imicrobial resistance a national security threat that causes over 2
illion illnesses, $20–35 billion in excess direct healthcare costs,
35 billion in loss of productivity, and 8 million additional hospital
ays each year in the US [7] . Worldwide, it is estimated that by
050, 10 million people will die annually from antibiotic-resistant
nfections [8] . 
GNB are among the most alarming antibiotic-resistant
athogens as they are often resistant to multiple antibiotic
lasses and capable of rapidly spreading resistance genes through
obile genetic elements. For example, the pandemic emergence of
he highly drug-resistant clone of Escherichia coli , sequence type
31 (ST131), occurred in less than 10 years [9] . Limited surveil-
ance data suggest that in some regions of the world nearly 70%
f GNB clinical isolates produce extended-spectrum β-lactamases
ESBLs), which make them resistant to most β-lactam antibiotics
10, 11] . Even more alarming is that in some studies, resistance to
arbapenems, known as last-resort antibiotics, has been reported
n up to 68% of Klebsiella pneumoniae isolates [12–15] . India,
hich has one quarter of the global burden of MDR TB, is also
he epicenter of carbapenem-resistant, New Delhi-metalloprotease
NDM)-producing strains of Enterobacteriaceae [16] , which have
een found contaminating environmental sources [17] . As with
DR TB, international travel has facilitated spread of MDR
NB, with travel to regions of the world with high ESBL and
arbapenem-resistant Enterobacteriaceae (CRE) rates identiﬁed as ander the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ). 
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Reproduced with permission from [26]. Shown is % of extended-spectrum β-lactamase (ESBL)-producing isolates.
Fig. 1. MDR TB (A) and extended-spectrum β-lactamase (ESBL)-producing E. coli (B) are prevalent in similar regions of the world. 
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m  isk factor for acquisition of MDR GNB in several studies [18–22] .
imilar to patients with MDR TB who must rely on second-line
nti-TB drugs, those with MDR GNB often receive second-line
gents that are more toxic and expensive but less effective than
rst-line therapies, contributing to poor outcomes. Mortality rates
or carbapenem-resistant Enterobacteriaceae infections range from
8-48% [23, 24] compared to 10% for carbapenem-susceptible
nfections [25] . In India alone, drug-resistant pathogens, many ofhich are GNB, are estimated to cause 58,0 0 0 neonatal deaths
26] . 
DR TB and MDR GNB are human-made problems 
Both MDR TB and MDR GNB have arisen through missteps at
he level of patients, providers, and health systems and are human-
ade problems. They have ﬂourished in regions of the world with
30 R. Banerjee, J.R. Starke / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 3 (2016) 28–34 
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n  impoverished or poorly functioning healthcare systems and insuﬃ-
cient laboratory capacity that hinders rapid diagnosis, appropriate
treatment and infection control interventions. These deﬁciencies,
in turn, create further selection pressure for emergence and trans-
mission of resistant pathogens [27–29] . The MDR TB and MDR GNB
epidemics are multifactorial in origin, but the main causes are mis-
use of antimicrobial drugs and poor infection control technique. 
The marked geographic variation in MDR TB prevalence is due
to differences in the quality and inﬂuence of national TB programs.
Regions with high MDR TB prevalence tend to have: poorly func-
tioning national TB programs that do not routinely administer TB
medications through Directly Observed Therapy (DOT) with subse-
quent poor patient adherence; poor quality of TB medications; a
signiﬁcant proportion of TB care given in the private sector; lack
of laboratory capacity, medications, and access to healthcare; and
inadequate infection control in healthcare facilities and congregate
settings leading to sometimes profound and sustained transmission
of MDR TB [30,31] . 
Similarly, antibiotic misuse and poor infection control are the
biggest drivers of GNB drug resistance. It is estimated that 60%
or more of hospitalized patients or residents of long-term care
facilities in the US receive antimicrobials and that up to half of
these antimicrobial prescriptions are inappropriate [4,32] . In US
ambulatory settings, there are 11 million unnecessary antibiotic
prescriptions given each year to children for management of viral
respiratory tract infections [33] . Antibiotic abuse is even more
rampant in low and middle income countries; these countries had
the greatest increase in antibiotic use between 20 0 0 and 2010
and tend to have the highest prevalence of MDR GNB ( Fig. 1 ) [26] .
India, followed closely by China, leads the world in total antibiotic
consumption [26] . Not surprisingly, they also have the greatest
number of MDR and XDR TB cases. Many low and middle income
countries also have variable and often poor quality of health-
care, limited laboratory capacity, and poor quality antimicrobial
agents that are commonly available over-the-counter, without a
prescription [26,27,34,35] . 
Throughout the world, antibiotics are also abused in agricul-
ture, where they are used as growth promoters or for routine
mass prophylaxis of livestock, thereby contributing to the rise in
drug resistant pathogens. It is no surprise that many of the coun-
tries consuming the largest amounts of antibiotics for livestock
(e.g. China, India, Russia) also have high prevalence of MDR GNB
[14,26] . In contrast, the European Union banned use of antibiotics
as feed additives in agriculture in 2006 which led to substantial
decreases in antibiotic sales for livestock in many countries in
Western Europe [26] . There is some data from high income coun-
tries that decreased antibiotic use in farm animals is associated
with lower prevalence of antibiotic resistant strains in humans
[36] . Lastly, as with MDR TB, there are numerous examples of poor
infection control leading to acquisition and spread of MDR GNB
within healthcare settings [37–40] . Enhanced infection control
interventions such as active surveillance of infected or colonized
individuals, and patient and/or staff cohorting were critical for
halting outbreaks of carbapenem-resistant Enterobacteriaceae in
Israel [41] and the U.S. National Institutes of Health [40] . 
MDR TB in New York City: a success story in curtailing 
emergence and spread of drug resistance 
New York City was the epicenter of MDR TB in the US in the
1980s and 1990s, largely due to a “perfect storm” of decreased
funding for TB control programs, growth in HIV-infected, poor,
homeless, and immigrant populations, and poor infection control
in hospital settings [42] . Between 1978 and 1992 the number
of TB cases in New York City tripled, reaching a case rate of
222/10 0,0 0 0 in some parts of the city [43] . The proportion of TBases caused by MDR strains approached 25%, with case fatality
ates of greater than 80% [43] . There was “massive noncompli-
nce” among TB patients, with TB treatment completion rates as
ow as 11% [44] . In 1991, 61% of the nation’s MDR TB cases oc-
urred in New York City, and many were in individuals without
revious TB treatment history, suggesting primary transmission of
esistant strains. Moreover, several MDR TB outbreaks were docu-
ented in hospitals and congregate settings that lacked effective
nfection control procedures in both ambulatory and inpatient set-
ings, and allowed crowding of inadequately treated TB patients. 
Only after TB control programs were bolstered through in-
reased funding (ultimately costing over $1 billion), did the epi-
emic in New York end [42] . Within two years of making program-
atic improvements such as increased staﬃng, improved labora-
ory diagnostics, and better infection control, there was a substan-
ial decrease in the number of TB cases. The city was able to pro-
ide TB therapy via DOT to more than 1200 patients by 1994, as
pposed to fewer than 50 in 1983, leading to TB treatment com-
letion rates above 90% [43] . Improved practices for screening, iso-
ation, and follow-up of incarcerated individuals and better infec-
ion control in hospitals and congregate settings contributed to re-
uced transmission. Broader use of M. tuberculosis drug suscepti-
ility testing and genotyping led to earlier diagnosis of drug resis-
ance, more timely initiation of effective therapy, and understand-
ng of transmission pathways. A combination of political commit-
ent, suﬃcient funding, and infrastructure development were the
ornerstones of controlling MDR TB in New York City, where nearly
ll MDR TB cases are now imported, rather than created locally
42] . 
esponse to the MDR TB epidemic 
The global TB community has responded to the emergence and
pread of MDR TB through a variety of multidisciplinary strategies,
s was done in New York City. It has been approached from both
he personal health – such as adherence to therapy – and the pub-
ic health points of view. Below we highlight core TB control strate-
ies that are relevant to the management of the current epidemic
f MDR GNB. 
ntimicrobial stewardship 
The phrase “antimicrobial stewardship” has usually been
eserved for discussions of antibiotics like penicillins or
ephalosporins and historically has not been used when re-
erring to TB [45] . However, the global TB community has long
een practicing stewardship of TB medications. It is well-known
hat among risk factors for drug-resistant TB disease are prior
B treatment, poor medication adherence, inadequate medication
egimens or poor drug quality which can lead to subtherapeutic
rug levels and acquired drug resistance. The World Health Or-
anization, Stop TB Partnership, and Global Drug Facility began
roviding low resource areas with affordable, high quality TB
edications, including pediatric formulations and second-line
rugs for treatment of MDR TB in 2001 [46, 47] . Directly observed
herapy (DOT) has been implemented by many public health
epartments worldwide for decades to improve TB treatment
dherence and completion rates, and to lower the incidence of
evere adverse drug reactions [48] . More recently, to provide
OT to diﬃcult-to-reach populations, strategies such as video or
martphone-assisted-DOT and other eHealth innovations are being
mplemented [49] . Appropriate doses and durations of anti-TB
herapy based on resistance phenotypes, patient characteristics,
nd clinical disease have been well-established through high
uality and well-funded clinical trials, and are recommended in
ational and international TB treatment guidelines [50,51] . Lastly,
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m  se of the novel and costly drug, bedaquiline, is restricted in order
o prevent its overuse, preserve its activity, monitor its safety, and
ontrol costs [52] . All of the above strategies demonstrate that the
B community has embraced the concept of global antimicrobial
tewardship of TB medications in order to optimize clinical out-
omes, reduce transmission and toxicity, and prevent development
f drug resistance. 
apid diagnostic test development and implementation 
One of the major barriers to timely TB diagnosis and treatment
s limited laboratory capacity and lack of timeliness for M. tubercu-
osis identiﬁcation and resistance detection in resource-limited set-
ings. It is estimated that greater than 80% of MDR TB cases that
rise each year remain microbiologically undiagnosed [53] . To ad-
ress this limitation, signiﬁcant resources have been invested in
apid, point-of-care molecular diagnostics for TB, leading to the
evelopment of line probe assays, ﬂuorescence microscopy, liq-
id cultures, and the Xpert MTB/RIF assay [54] . Among these, the
pert MTB/RIF assay, which simultaneously detects M. tuberculo-
is complex DNA and rifampin resistance (a reliable surrogate for
DR TB) [55] from clinical specimens within 2 h, and does not
equire specialized laboratory infrastructure or technologist skills,
as selected for global roll-out. This assay was developed within 4
ears through a collaboration among academic and industry part-
ers, including Cepheid, FIND, University of Medicine and Dentistry
f New Jersey (UMDNJ), the National Institutes of Health (NIH),
nd the Bill and Melinda Gates Foundation [54,56,57] . Critical for
he development and programmatic implementation of this assay
as the pooling of resources needed for test development, clin-
cal validation trials, and ﬁeld evaluations, and industry partners
ho agreed to ﬂexible product pricing [57] . It was endorsed by the
HO in 2010 and soon after Ministries of Health of high TB bur-
en countries developed guidelines, policies, and frameworks for
pert MTB/RIF implementation [58] . 
Implementation of the Xpert MTB/RIF has led to a 3 fold
ncrease in MDR TB case detection rates globally [59] , with 116
ountries using over 10 million Xpert MTB/RIF tests, including
.8 million in 2014 alone [1, 60] . Yet while Xpert MTB/RIF is the
ost exciting innovation in TB diagnostics in over 100 years, and
hould, in theory, enable more timely diagnosis of MDR TB, facil-
tating prompt and optimal treatment for MDR TB patients, it has
imitations, including inability to distinguish MDR isolates from
hose that have rifampin mono-resistance, or those containing
poB mutations that are silent, clinically insigniﬁcant, or outside of
he targeted region of the gene [61] . In addition, in some places
he impact of Xpert MTB/RIF has been limited by cost, infras-
ructure, and health system challenges [62] . In response, the cost
f required cartridges was recently reduced through a ﬁnancial
greement among the manufacturer, the Gates foundation, USAID,
EPFAR, and UNITAID [63] . It has also become clear that enhanc-
ng systems throughout the care continuum of TB is essential for
he Xpert MTB/RIF test to have optimal impact. For example, in
ndia, although MDR TB case detection rates have increased since
mplementation of the Xpert MTB/RIF, only 20,0 0 0 of an estimated
4,0 0 0 patients with MDR TB were placed on appropriate therapy
n 2013 [64] . Similarly, in South Africa, despite use of the Xpert
TB/RIF assay, only 70% of MDR TB patients were started on
ffective treatment within 1 month due, in part, to poor provider
ompliance with the national recommendation to order a second,
onﬁrmatory sputum sample [65] . 
Adoption of the Xpert MTB/RIF has been slow in certain regions
n part due to distrust of the new test, lack of clarity about testing
lgorithms [66, 67] , insuﬃcient funding for programmatic scale up,
nd lack of available second-line TB treatments [68, 69] . As more
DR cases are diagnosed, countries must be able to treat patientsith second line drugs, which are 50–200 times more costly per
atient than are ﬁrst line drugs [56] and often of poor quality [54,
7, 66] . Since the roll-out, studies have demonstrated that the per-
ormance, impact, and cost-effectiveness of the Xpert MTB/RIF test
ary by disease prevalence, population, resources, and current test-
ng and treatment algorithms [54] . It has become clear that to op-
imally impact the care of patients, rapid test development alone
s not suﬃcient. Rather, systems must be in place to ensure access
o new diagnostics, conﬁrmation of rapid test results with stan-
ard culture and susceptibility testing, appropriate use and inter-
retation of rapid testing, and access to second-line drugs, when
eeded. Evaluation of the Xpert MTB/RIF assay’s impact in various
ettings and different implementation models is ongoing [70] . 
ew drug development 
The pharmaceutical industry had, until recently, pulled out of
he antimicrobial drug development market, stalling development
f new antibiotics against Mycobacterium tuberculosis and other
acteria. The most recently developed ﬁrst line drug for TB was
ifampin which became available in 1968. In place of industry,
overnment and non-government organizations such as the NIH
nd the Bill and Melinda Gates Foundation stepped up to fund
ranslational research for TB drug development [57] . Not–for-proﬁt
roduct development partnerships were also created, including the
lobal Alliance for TB Drug Development, TB Drug Accelerator, the
illy Early TB Drug Discovery Initiative, More Medicines for TB,
nd Orchid [53] . Several advocacy groups such as Treatment Action
roup ( http://www.treatmentactiongroup.org ) and RESULTS ( http:
/www.results.org/issues/global _ health _ tuberculosis/ ) were also in-
trumental in increasing political will and support for TB drug re-
earch. After 40 years without any new TB drugs, Bedaquiline, a di-
rylquinoline, received accelerated FDA approval in 2012 [71] and
elamanid, a nitroimidazole, received approval from the European
edicines Agency in 2013, both approved for treatment of MDR
B [53,72] . In addition, PA-824, another nitroimidazole, will soon
e evaluated in phase III clinical trials in combination with mox-
ﬂoxacin and pyrazinamide. Shorter course TB therapy was evalu-
ted in clinical trials and, in 2011, 3 months of once-weekly iso-
iazid and rifapentine was endorsed by the CDC for treatment of
atent TB infection, the ﬁrst new regimen in decades for the treat-
ent of latent TB infection [73] . The recent successes in TB drug
evelopment underscore the importance of adequate investment in
asic research, product development partnerships, economic incen-
ives for pharmaceutical companies, an accelerated approvals pro-
ess, infrastructure for clinical trials in order to maintain robust
ipelines for antibacterial drug development, and the vital role of
atient advocacy. 
nhanced surveillance 
The World Health Organization (WHO) established a global TB
eporting system in 1995 that has become invaluable to national
nd global TB programs. The 20th edition of the Global Tuberculo-
is Report was published this year and compiled TB data from 205
ountries accounting for 99% of the world’s population [1] . Even
igh TB burden countries like India have now instituted mandatory
otiﬁcation of TB cases [1] . This level of surveillance makes it pos-
ible to obtain national and global estimates of TB disease burden,
rug resistance, treatment completion rates, and clinical outcomes
1] . Strengthening TB surveillance systems has thus helped identify
reas for intervention, formulate national and global strategies for
mproved TB control, and allowed public health agencies to set at-
ainable and measurable targets. For example, targets of halving TB
ortality and TB prevalence in 2015 compared to 1990 were met
32 R. Banerjee, J.R. Starke / Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 3 (2016) 28–34 
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ein several WHO regions [1] . Other targets – that all countries re-
port outcomes for notiﬁed MDR TB cases and that MDR TB treat-
ment success rates exceed 75% – have not yet been met and re-
quire further programmatic effort s [1] . 
Infection control 
As demonstrated by MDR TB management in New York in the
1990s, rapid diagnosis and effective treatment of patients with
TB must be combined with effective infection control measures
to reduce transmission of drug-resistant TB [31,74–76] . A few
studies in low resource, high TB prevalence areas demonstrate
that community-based TB treatment is successful and avoids con-
gregation in hospitals [77–79] . In South Africa, where nosocomial,
drug-resistant TB outbreaks have occurred, home-based treatment
for both MDR TB and HIV, with administration of medications
by nurses and community health workers during home visits,
yielded high treatment completion and cure rates [77] . Additional
strategies include improving ventilation in healthcare facilities,
optimizing outdoor waiting areas, building TB isolation facilities,
redesigning patient triage and ﬂow, reducing hospitalization times,
and using germicidal ultraviolet air disinfection [30] . 
Response to the MDR GNB epidemic 
The global response to antibiotic resistant GNB has been slow
and disappointing, but now is focusing similar efforts on the same
ﬁve strategies that have guided the approach used in TB: (1) en-
hanced antimicrobial stewardship; (2) development of rapid di-
agnostics that more quickly identify pathogens and detect drug
resistance; (3) new antimicrobial development; (4) strengthened
surveillance systems; and (5) enhanced infection control prac-
tices. While TB has always been recognized and approached as
both a public health and personal health problem, tradition-
ally GNB drug resistance has been approached only on a per-
sonal level; the public health approach has only recently been
applied to GNB drug resistance. Earlier this year, the US Na-
tional Strategy for Combating Antibiotic Resistant Bacteria was un-
veiled [80] . This action plan emphasizes several key areas and in-
cludes regulatory mandates and economic incentives to facilitate
implementation [80] . 
The plan highlights the importance of strengthening antibiotic
stewardship and tracking antibiotic use in humans and animals.
This is analogous to how the TB community responded to MDR TB
by becoming better stewards of TB medications through the pro-
vision of DOT and enhanced surveillance of treatment regimens,
adherence and completion. In 2016, CMS will require all acute
care hospitals to have an antimicrobial stewardship program and
report data on inpatient antimicrobial use to the CDC’s National
Healthcare Surveillance Network. The National Strategy also cites
the importance of conducting stewardship in all healthcare set-
tings, including long-term and ambulatory care centers. Moreover,
legislation has been introduced to the US Congress to eliminate
nontherapeutic use of antibiotics in animals (Preventing Antibiotic
Resistance Act) [81] . Additionally, the White House hosted a Fo-
rum on Antibiotic Stewardship, attended by a variety of stakehold-
ers, including advocacy groups like the Safe Care Campaign (safe-
carecampaign.org), that have begun raising awareness about MDR
GNB. Furthermore, last year the Obama Administration announced
a $20 million prize for development of rapid, point-of-care di-
agnostics that identify drug resistant bacteria. Similar regulatory
mandates, patient advocacy, and ﬁnancial incentives for rapid di-
agnostic development were critical to the recent successes in TB
care. However, as demonstrated by the variable impact of the Xpert
MTB/RIF assay in different settings, methods to most effectivelymplement novel diagnostics for MDR GNB will require further
tudy. 
There has also been recent legislation providing economic in-
entives for pharmaceutical companies to reenter the antibacterial
rug development arena. In part due to successfully lobbying by
he Infectious Disease Society of America and its call for 10 new
ntibiotics by 2020 (10 × 20 initiative), the Generating Antibiotic
ncentives Now (GAIN) Act, was passed in 2012 and offers a 5-year
atent extension and an accelerated approval process for new
ntibacterial agents that are considered infectious disease products
82] . Legislation has also been introduced to accelerate the FDA
pproval process for antimicrobial agents for the treatment of pa-
ients with serious or life-threatening infections who have limited
reatment options (Promise for Antibiotics and Therapeutics for
ealth (PATH) Act [83] . These effort s have met with some success,
otably the recent FDA approvals of 2 new antibiotics with activity
gainst resistant Gram negative bacteria, ceftolozane/tazobactam
nd ceftazidime/avibactam. Similar economic incentives and
ublic/private partnerships were critical for new TB drug
evelopment. 
More systematic evaluation of bacterial drug resistance at
nstitutional, national, and global levels has been essential for
DR TB control and is incorporated into the National Action Plan
or combatting antibiotic resistant bacteria [80] . The US plans
o create regional public health laboratory networks to molec-
larly characterize resistant bacteria and has started a multisite
ram negative surveillance initiative through the US Centers for
isease Control and Prevention [23] . Europe has a multinational
urveillance network called the European Antimicrobial Resis-
ance Surveillance network (EARS-Net) that collects and reports
esistance data from national surveillance systems [15] . However,
mproved laboratory capacity and surveillance systems are badly
eeded in other parts of the world, particularly in low income na-
ions with high prevalence of MDR GNB [15] . Some countries such
s India and Vietnam have started developing national surveillance
etworks [15, 26] . The WHO provides free software for countries
o collect and share their antibiotic resistance data (WHONET)
 http://www.whonet.org ), yet in the recent WHO report on global
ntimicrobial resistance, data were inconsistently reported [84] .
ecognizing the gaps in antimicrobial resistance surveillance in
any regions, the Bill and Melinda Gates Foundation, that has
upported much TB research, recently called for proposals involv-
ng novel methods to track the global burden of antimicrobial
esistance. 
Just as strengthening infection control practices have been crit-
cal to reducing transmission of MDR TB, so better infection con-
rol is recognized as important for control of MDR GNB. Improving
and hygiene, active surveillance, contact isolation for patients in-
ected or colonized with MDR GNB, and enhanced environmental
leaning have been recommended by European and US agencies in
rder to reduce spread of MDR GNB in healthcare settings [85–87] .
mplementation of such bundled interventions has reduced preva-
ence of carbapenem-resistant Enterobacteriaceae (CRE) in acute
are hospitals and during outbreaks [39, 88] . For example, in 2007,
hen Israel was experiencing a nationwide carbapenem-resistant
lebsiella pneumoniae outbreak, the country’s Ministry of Health
mplemented enhanced surveillance systems and infection control
ractices at hospitals and long term care facilities. A combination
f sharing surveillance data among institutions, molecular charac-
erization of strains, identiﬁcation and isolation of carriers, cohort-
ng of colonized patients and staffs, and active case ﬁnding, led to
 10-fold reduction in transmission of these strains [89,90] . A sim-
lar approach has been used to control outbreaks of CRE in the US
39,91] . Enhancing infection control in areas with high prevalence
f MDR GNB is critical to controlling this epidemic, and has been
mphasized by the WHO [92,93] . 
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Table 1 
Principles of TB control that can be applied to management of multidrug-resistant Gram negative bacilli (MDR GNB). 
1. Raise awareness that MDR GNB are a public health problem that can affect anyone 
2. Implement and enforce robust antimicrobial stewardship interventions, especially in the private sector 
3. Implement and enforce robust infection control and prevention interventions in healthcare and long-term care facilities 
4. Create systems for surveillance and mandatory reporting of MDR GNB and facilitate appropriate responses by health departments 
5. Foster new drug development through partnerships between industry and academia 
6. Build political will to incentivize antibiotic and diagnostic test development through regulation 
7. Invest in and fast-track new drug development 
8. Encourage not-for-proﬁt foundations and governments to support both basic science and translational research 
9. Support behavioral research to determine how to change the behaviors and attitudes of prescribers and patients in regard to antimicrobial use 
10. Enhance advocacy to raise awareness of MDR GNB and to encourage industry, funders and governments to support appropriate interventions 
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 onclusions 
There are striking similarities in the geographic regions ( Fig. 1 )
nd underlying health system deﬁciencies where both MDR TB and
DR GNB are prevalent. Many of the strategies used to approach
DR TB will also be needed to address the MDR GNB crisis ( Table
 ). Although MDR TB remains a serious public health problem, and
ajor obstacles remain in global TB control, the availability of data
escribing the magnitude of the problem, the availability of new
rugs and the global roll out of Xpert MTB/RIF have changed the
andscape of TB control. The response to MDR TB, while not per-
ect, is as an example of how suﬃcient resources, combined with
trong multinational and public-private partnerships, advocacy and
olitical will, can positively impact global public health. This pro-
ides hope that the approaches to combating MDR GNB outlined in
he Obama Administration’s National Action Plan, may be effective.
We have learned from TB control effort s that along with in-
ovations like new drugs and diagnostics, there will also need
o be strategies to increase global laboratory capacity, make new
rugs and diagnostics affordable for resource limited areas, provide
ood stewardship of new and existing antibiotics, improve surveil-
ance systems and infection control effort s, and strengthen health
ystems in order to match increased diagnostic capacity with in-
reased treatment capacity for MDR GNB infections. 
We all play important roles in addressing the global MDR GNB
roblem ( Table 1 ). Individual clinicians must practice good antimi-
robial stewardship and encourage colleagues to prescribe antibi-
tics responsibly; infection control practitioners must design and
nforce interventions that prevent MDR GN spread in healthcare
acilities; public health oﬃcials must create and strengthen re-
ional, national, and international surveillance systems for MDR
NB; and policy makers must foster international collaborations
nd partnerships among the scientiﬁc community, agriculture in-
ustry, pharmaceutical industry, regulators, not-for-proﬁt organiza-
ions and policy makers, to tackle the global MDR GNB problem
hat is ﬁnally getting the attention it deserves. 
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